Biolipox, Inflazyme, Orexo deal

Biolipox completed its previously announced acquisition of IZP's leukocyte selective anti-inflammatory drugs (LSAID) and phosphodiesterase-4 (PDE-4) inhibitor programs and its Prodaptin tethering technology (see BioCentury, Oct. 1). ...